Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
Μaria Dalamaga, Ιrene Karampela, Christos S. Mantzoros
Metabolism (2020) Vol. 109, pp. 154282-154282
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment
Esmé Jansen van Vuren, Stephan F. Steyn, C. Brink, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 135, pp. 111200-111200
Open Access | Times Cited: 97
Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach
S.T.R. Moolamalla, Rami Balasubramanian, Ruchi Chauhan, et al.
Microbial Pathogenesis (2021) Vol. 158, pp. 105114-105114
Open Access | Times Cited: 68
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 68
Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives
Μaria Dalamaga, Gerasimos Socrates Christodoulatos, Ιrene Karampela, et al.
Current Obesity Reports (2021) Vol. 10, Iss. 3, pp. 214-243
Open Access | Times Cited: 64
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
Claire Lugnier, Hayder M. Al‐kuraishy, Éric Rousseau
Biochemical Pharmacology (2021) Vol. 185, pp. 114431-114431
Open Access | Times Cited: 61
Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice
Vinícius Amorim Beltrami, Flávia Rayssa Braga Martins, Débora Gonzaga Martins, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Open Access | Times Cited: 1
Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies
Ioannis Lempesis, Dimitrios Tsilingiris, Junli Liu, et al.
Metabolism Open (2022) Vol. 15, pp. 100208-100208
Open Access | Times Cited: 38
The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
Claire Lugnier
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10616-10616
Open Access | Times Cited: 32
Quinazoline-Schiff base conjugates: in silico study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins
Mostafa A. Mansour, Asmaa M. AboulMagd, Hamdy M. Abdel‐Rahman
RSC Advances (2020) Vol. 10, Iss. 56, pp. 34033-34045
Open Access | Times Cited: 46
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Mauro Giorgi, Silvia Cardarelli, Federica Ragusa, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5338-5338
Open Access | Times Cited: 45
Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19
Éric Azabou, Guillaume Bao, Rania Bounab, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 36
Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic
Natalia G. Vallianou, Dimitrios Tsilingiris, Gerasimos Socrates Christodoulatos, et al.
Metabolism Open (2021) Vol. 10, pp. 100096-100096
Open Access | Times Cited: 35
Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment
Raviteja Chemboli, Ravikumar Kapavarapu, Deepti Kolli, et al.
Journal of Molecular Structure (2021) Vol. 1230, pp. 129868-129868
Open Access | Times Cited: 34
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
Milo Gatti, Fabrizio De Ponti
Pharmaceutics (2021) Vol. 13, Iss. 3, pp. 302-302
Open Access | Times Cited: 29
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis, Jun‐Li Liu, Μaria Dalamaga
Metabolism Open (2022) Vol. 16, pp. 100220-100220
Open Access | Times Cited: 21
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Taymour Mostafa
Sexual Medicine Reviews (2020) Vol. 9, Iss. 1, pp. 15-22
Open Access | Times Cited: 29
Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: an observational cross-sectional study
Μaria Dalamaga, Giovanna Muscogiuri, Georgia Paganitsa, et al.
International Journal of Food Sciences and Nutrition (2021) Vol. 72, Iss. 6, pp. 848-860
Closed Access | Times Cited: 24
Gut probiotic Lactobacillus rhamnosus attenuates PDE4B-mediated interleukin-6 induced by SARS-CoV-2 membrane glycoprotein
M.T. Pham, Albert Jackson Yang, Ming‐Shan Kao, et al.
The Journal of Nutritional Biochemistry (2021) Vol. 98, pp. 108821-108821
Open Access | Times Cited: 24
Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice
Chia-Chih Liao, Huang‐Ping Yu, Shih-Chun Yang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 19
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis
Ignatios Ikonomidis, George Pavlidis, Nikolaos P.E. Kadoglou, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 172-172
Open Access | Times Cited: 13
Integrin α 5 β 1 contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent interaction
Heng Zhang, Zhengli Wang, Huong T. T. Nguyen, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 50
Open Access | Times Cited: 8
The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
Hoang Oanh Nguyen, Tiziana Schioppa, Laura Tiberio, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 12
PdCl2-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor
B. Thirupataiah, Guntipally Mounika, Gangireddy Sujeevan Reddy, et al.
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113514-113514
Closed Access | Times Cited: 15
PDE5 inhibitors: breaking new grounds in the treatment of COVID-19
Ryan Varghese, Gargi Digholkar, Jainam Karsiya, et al.
Drug Metabolism and Personalized Therapy (2023)
Open Access | Times Cited: 6
<p>A Review on Currently Available Potential Therapeutic Options for COVID-19</p>
Solmaz Ohadian Moghadam
International Journal of General Medicine (2020) Vol. Volume 13, pp. 443-467
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top